MTOR and ovarian cancer: In addition, it was reported that NOTCH1 mutation exhibits oncogenic properties via the activation of the EGFR-PI3K-AKT pathway in HNCC [14], and HNCC with mutated NOTCH1 was more vulnerable to therapeutic PI3K/mTOR inhibition [20], which implied that PI3K inhibitors may benefit patients with ovarian cancer lymph node metastasis.